Trial · NCT01129674
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to discontinuation due to adverse events | Baseline through 52 weeks | |
| Secondary | Change from baseline to 52 weeks endpoint in PANSS (Positive and Negative Syndrome Scale) | Baseline, 52 weeks | |
| Secondary | Change from baseline to 52 week endpoint in Clinical Global Impression-Severity (CGI-S) | Baseline, 52 weeks | |
| Secondary | Change from baseline to 52 week endpoint in NSA-16 (16-item Negative Symptoms Assessment) | Baseline, 52 weeks | |
| Secondary | The number of patients with statistically significant changes (treatment emergent ideation and behavior; improvement) based on the Columbia Suicide Severity Rating Scale (C-SSRS) | 52 weeks, 104 weeks, end of study | |
| Secondary | Change from baseline to 52 week endpoint in PSP scale (Personal and Social Performance) | Baseline, 52 weeks | |
| Secondary | Change from baseline to 52 week endpoint in the SWN Scale (Subjective Well-Being Under Neuroleptic Treatment) | Baseline, 52 weeks | |
| Secondary | Change from baseline to 104 week endpoint in the Schizophrenia Resource Use Model (S-RUM) | Baseline, 104 weeks | |
| Secondary | Change from baseline to 104 week endpoint in the EuroQoL Questionnaire-5 Dimension (EQ-5D) | Baseline, 104 weeks | |
| Secondary | Change from 52 week to 104 week endpoint in PANSS (Positive and Negative Syndrome Scale) | 52 weeks, 104 weeks | |
| Secondary | Change from 52 week to 104 week endpoint in Clinical Global Impression-Severity (CGI-S) | 52 weeks, 104 weeks | |
| Secondary | Change from 52 week to 104 week endpoint in NSA-16 (16-item Negative Symptoms Assessment) | 52 weeks, 104 weeks | |
| Secondary | Change from 104 week to study endpoint in Clinical Global Impression-Severity (CGI-S) | 104 weeks, end of study | |
| Secondary | Change from baseline to 104 week endpoint in PSP scale (Personal and Social Performance) | Baseline, 104 weeks | |
| Secondary | Change from baseline to 104 week endpoint in the SWN Scale (Subjective Well-Being Under Neuroleptic Treatment) | Baseline, 104 weeks | |
| Secondary | Change from Baseline to 52 week endpoint in the Schizophrenia Resource Use Model (S-RUM) | Baseline, 52 weeks | |
| Secondary | Change from 104 week to study endpoint in the EuroQoL Questionnaire-5 Dimension (EQ-5D) | 104 weeks, end of study | |
| Secondary | Change from baseline to 52 weeks endpoint in PANSS (Positive and Negative Syndrome Scale) in a genetically defined subgroup | Baseline, 52 Weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01129674/registered